Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 15:10:101759.
doi: 10.1016/j.jaccas.2023.101759.

TTR Amyloidosis: Current State of Affairs and Promise for the Future

Yevgeniy Brailovsky  1 , Indranee Rajapreyar  1 , Rene Alvarez  1
Affiliations
Editorial

TTR Amyloidosis: Current State of Affairs and Promise for the Future

Yevgeniy Brailovsky et al. JACC Case Rep. .
No abstract available

Keywords: chronic heart failure; diastolic heart failure; preserved ejection fraction.

PubMed Disclaimer

Conflict of interest statement

Dr Brailovsky has received an educational grant from Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

Figure 1
Figure 1
Example Multidisciplinary Team Example of a multidisciplinary team involved in the care of patients with systemic amyloidosis and diagnostic work-up. The figure were created using BioRender. AL = amyloidosis light chain; ATTR = transthyretin amyloidosis; ECG = electrocardiogram; h = healthy; H/CL = heart to contralateral ratio; SPECT = single-photon emission computed tomography; Tc-99m-PYP = technetium Tc 99 m pyrophosphate; wt = wild-type.
Figure 2
Figure 2
Systemic Manifestations of ATTR Systemic manifestations of transthyretin amyloidosis (ATTR) include gastrointestinal (GI), cardiac, musculoskeletal, neuropathic, among others. This figure were created using BioRender.
Figure 3
Figure 3
Pathophysiology and Therapeutic Targets of Systemic ATTR Pathophysiology and therapeutic targets of systemic transthyretin amyloidosis (ATTR) are shown. This figure were created using BioRender. TTR = transthyretin; TUDCA = tauroursodeoxycholic acid.
None
See this image and copyright information in PMC

References

    1. Hahn V.S., Yanek L.R., Vaishnav J., et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. Heart Fail. 2020;8(9):712–724. - PMC - PubMed
    1. González-López E., Gallego-Delgado M., Guzzo-Merello G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594. - PubMed
    1. Castano A., Narotsky D.L., Hamid N., et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–2887. - PMC - PubMed
    1. Elgendy I.Y., Elbadawi A. Transcatheter edge-to-edge repair of the MV among patients with cardiac amyloidosis: ready for prime time? Cardiovasc Interv. 2022;15(17):1759–1761. - PubMed
    1. Godara A., Riesenburger R.I., Zhang D.X., et al. Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid. 2021;28(4):226–233. - PubMed

Publication types